Levothyroxine sodium is under clinical development by Xeris Biopharma and currently in Phase II for Hypothyroidism. According to GlobalData, Phase II drugs for Hypothyroidism have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Levothyroxine sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Levothyroxine sodium overview
Levothyroxine sodium (XP-8121) is under development for the treatment of hypothyroidism. It is administered by subcutaneous route. The therapeutic candidate acts by targeting thyroid hormone receptor, developed based on XeriSol formulation technology.
Xeris Biopharma overview
Xeris Biopharma (XERIS) is the specialty pharmaceutical company that develops novel technology platforms to develop and commercialize stable injectable and infusible drug formulations. The company offers products such as Gvoke HypoPen, Levothyroxine and Hypothyroidism, Ogluo, Recorlev and Keveyis. Gvoke HypoPen is a liquid-stable, ready-to-use glucagon, is a prescription drug used to treat severe hypoglycemia. Ogluo is used to treat extreme hypoglycemia. Recorlevis a cortisol synthesis inhibitor used to treat endogenous hypercortisolism. Keveyis is a prescription medication used to treat conditions including primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and others. It caters to caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.
For a complete picture of Levothyroxine sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
